Meeting
2023 ASCO Annual Meeting
Distinguishing between cancer-related mutations and clonal hematopoiesis using cell-free RNA (cfRNA) expression levels in a machine learning model.
Authors
Maher Albitar
Genomic Testing Cooperative, Irvine, CA
Maher Albitar , Hong Zhang , Andrew Ip , Jeffrey Estella , Ahmad Charifa , Wanlong Ma , Arash Mohtashamian , Martin Gutierrez , Andrew L Pecora , Andre Goy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3043)
DOI
10.1200/JCO.2023.41.16_suppl.3043
Abstract #
3043
Poster Bd #
241
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Real world results of liquid biopsy in stage 3/4 solid tumors and potential ''clinical actionability."
First Author: Rebecca Christian Arend
Poster
2023 ASCO Annual Meeting
Clonal hematopoiesis (CH) associated mutations in patients with advanced solid tumors enrolled in phase I clinical trials.
First Author: Julieta Rodriguez
Poster
2020 Gastrointestinal Cancers Symposium
Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.
First Author: Francesca Battaglin
Poster
2019 Breakthrough
Plasma circulating tumor DNA-based genetic profiling of lung cancer patients in Vietnam using ultra-deep massive parallel sequencing with unique identifier tagging.
First Author: Huy Phuoc Do